_version_ |
1797279723935498240
|
collection |
DOAJ
|
first_indexed |
2024-03-07T16:31:10Z
|
format |
Article
|
id |
doaj.art-0475c097a3044ac8b85379d7cb898798
|
institution |
Directory Open Access Journal
|
issn |
2572-9241
|
language |
English
|
last_indexed |
2024-03-07T16:31:10Z
|
publishDate |
2023-03-01
|
publisher |
Wiley
|
record_format |
Article
|
series |
HemaSphere
|
spelling |
doaj.art-0475c097a3044ac8b85379d7cb8987982024-03-03T10:39:05ZengWileyHemaSphere2572-92412023-03-0173e85610.1097/HS9.0000000000000856202303000-00010Correction Notice: Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myelomahttp://journals.lww.com/10.1097/HS9.0000000000000856
|
spellingShingle |
Correction Notice: Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
HemaSphere
|
title |
Correction Notice: Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
|
title_full |
Correction Notice: Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
|
title_fullStr |
Correction Notice: Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
|
title_full_unstemmed |
Correction Notice: Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
|
title_short |
Correction Notice: Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
|
title_sort |
correction notice carfilzomib pomalidomide and dexamethasone as second line therapy for lenalidomide refractory multiple myeloma
|
url |
http://journals.lww.com/10.1097/HS9.0000000000000856
|